The complete guide to FDA-approved peptides

The peptide approval gap

Most peptides discussed online are not FDA-approved. Of the hundreds of sequences biohackers and longevity enthusiasts talk about, only a fraction have completed the clinical trial process. That gap determines what a physician can prescribe, what insurance might cover, and what legal protection exists if something goes wrong.

Most peptides discussed in online communities are not FDA-approved. Out of the hundreds of peptide sequences that biohackers, bodybuilders, and longevity enthusiasts talk about, only a fraction have completed the rigorous clinical trial process required for FDA approval. The disconnect between what is popular and what is approved creates real confusion.

Peptide drugs are a large and growing class: more than 80 peptide drugs have reached the market worldwide, with dozens more in clinical development [1]. But the peptides dominating Reddit threads and Telegram groups, BPC-157, TB-500, ipamorelin, and CJC-1295, are not among them. They exist in a regulatory gray area: sometimes compoundable, widely used, but never subjected to the phase 1-2-3 trial pipeline that semaglutide or tirzepatide completed.

Understanding which peptides are actually approved, which are in the pipeline, and which are strictly research compounds is not just academic. It determines what a physician can legally prescribe, what insurance might cover, and what legal protections exist if something goes wrong.

FDA-approved peptide therapeutics

These peptide drugs completed the full FDA process: phase 3 data, a defined safety profile, and at least one approved indication. The list spans blockbuster metabolic drugs like semaglutide and tirzepatide through rare-disease treatments for Rett syndrome, Barth syndrome, hypoparathyroidism, and erythropoietic protoporphyria.

The following peptide drugs have completed the full FDA approval process. Each one has phase 3 clinical trial data, a defined safety profile, and at least one approved indication. They represent the gold standard of what peptide medicine looks like when it goes through the system.

Semaglutide

The most commercially successful peptide drug in history. Ozempic (subcutaneous injection, type 2 diabetes, 2017), Rybelsus (oral tablet, type 2 diabetes, 2019, the first oral GLP-1 receptor agonist), Wegovy (subcutaneous injection, weight management, 2021), and the oral Wegovy 25 mg tablet for weight management, the first oral GLP-1 approved for obesity. The STEP 1 trial showed 14.9% mean weight loss at 68 weeks [2]. The oral 25 mg version achieved 16.6% mean weight loss at 64 weeks in the OASIS 4 trial when treatment was adhered to, with roughly one in three participants reaching 20% or more [3].

Tirzepatide

A dual GIP/GLP-1 receptor agonist. Mounjaro (type 2 diabetes, May 2022), Zepbound (weight management, November 2023), and a December 2024 approval for obstructive sleep apnea, the first medication ever approved for OSA [4]. The SURMOUNT-5 head-to-head trial showed 20.2% weight loss versus 13.7% for semaglutide at 72 weeks [5].

Afamelanotide (Scenesse)

A subcutaneous implant approved in October 2019 for erythropoietic protoporphyria (EPP). This is what the peptide community knows as melanotan I. The implant is a bioabsorbable PLGA polymer placed roughly every two months. Critical distinction: it is not approved for tanning.

Setmelanotide (Imcivree)

An MC4R agonist. Daily subcutaneous injection approved in 2020 for rare genetic obesity (POMC, PCSK1, and LEPR deficiency), expanded to Bardet-Biedl syndrome in 2022 and to children aged 2 to 5 in 2024.

Trofinetide (Daybue)

An oral solution approved in March 2023 for Rett syndrome. The first and only drug for this condition. It is a synthetic analog of the N-terminal tripeptide of IGF-1.

Palopegteriparatide (Yorvipath)

A subcutaneous injection approved in August 2024 for hypoparathyroidism, the first and only FDA-approved treatment for it. It is a prodrug of PTH(1-34).

Elamipretide

A subcutaneous injection granted accelerated approval in September 2025 for Barth syndrome. The first mitochondria-targeted therapeutic. It binds cardiolipin on the inner mitochondrial membrane.

Bremelanotide (Vyleesi)

A subcutaneous injection approved in 2019 for hypoactive sexual desire disorder in premenopausal women.

Tesamorelin (Egrifta)

A subcutaneous injection approved in 2010 for HIV-associated lipodystrophy. It is a growth hormone-releasing hormone analog.

How peptides get into your body

The administration route decides bioavailability, convenience, and who can realistically use a drug. Roughly two-thirds of approved peptide drugs are injected subcutaneously because peptides are large, fragile molecules that the gut destroys. Oral, implant, and nasal routes each solve that problem differently, and each pays a different price.

The administration route determines bioavailability, convenience, and which patients can actually use a drug. Peptides are large, fragile molecules, and getting them into the bloodstream intact is one of the central challenges of peptide pharmacology.

Subcutaneous injection

Accounts for roughly 65% of approved peptide drugs. It is the default because peptides are large molecules that get destroyed in the gut. Absorption is reliable, bioavailability is high, and auto-injector pens have made the process almost trivial for patients. Semaglutide, tirzepatide, setmelanotide, bremelanotide, tesamorelin, palopegteriparatide, and elamipretide all use this route.

Oral delivery

Oral delivery was considered impossible for peptides until Novo Nordisk cracked it with SNAC (sodium N-[8-(2-hydroxybenzoyl)amino] caprylate) technology. SNAC creates a local pH buffer in the stomach that protects semaglutide from enzymatic degradation and enhances absorption across the gastric epithelium [6]. Even so, oral bioavailability is on the order of 1%, which is why oral Wegovy uses a 25 mg dose to reach an effect comparable to a 2.4 mg injection. Trofinetide (Daybue) is also administered orally, as a solution.

Subcutaneous implants

Implants provide weeks to months of sustained release. Afamelanotide's PLGA implant dissolves over about 60 days. Goserelin (Zoladex) uses the same concept for prostate cancer. Histrelin (Supprelin LA) lasts a full 12 months. The trade-off is a minor procedure for insertion.

Nasal spray

The nasal route bypasses first-pass liver metabolism and delivers peptides directly to the bloodstream through the nasal mucosa. Desmopressin for diabetes insipidus and calcitonin for osteoporosis use this route. Selank and Semax are administered nasally in Russia, where intranasal Semax has been studied in healthy volunteers [7], though neither has FDA approval.

Emerging delivery technologies

Lipid nanoparticles, transdermal microneedle patches, and hydrogel depots are all in active development. None have produced an FDA-approved peptide product yet, but oral non-peptide GLP-1 agonists such as orforglipron may change the landscape entirely by sidestepping the bioavailability problem altogether.

The pipeline: what is coming next

Three candidates are generating the most clinical interest: retatrutide, a triple agonist with the largest phase 3 weight-loss figure recorded so far, CagriSema, an amylin and GLP-1 combination under FDA review, and survodutide, a dual agonist aimed at liver disease rather than weight alone.

Three candidates are generating the most clinical excitement right now. Each one addresses a different unmet need, and all three could reshape their respective therapeutic areas.

Retatrutide

Eli Lilly's triple agonist (GIP, GLP-1, and glucagon receptors). Phase 2 data showed up to 24.2% weight loss at 48 weeks [8]. The pivotal phase 3 TRIUMPH-1 readout reported up to 28.3% mean weight loss at 80 weeks on the 12 mg arm in 2,339 participants, the largest figure reported in a phase 3 obesity trial to date. Further phase 3 readouts are expected across the TRIUMPH program, and the earliest realistic FDA decision window is 2027 to 2028. For a full breakdown of what the trial data showed and what questions remain, see our retatrutide TRIUMPH-1 results explainer.

CagriSema

Novo Nordisk's fixed-dose combination of cagrilintide (an amylin analog) and semaglutide. The NDA was submitted in December 2025 and remains under FDA review, with company guidance pointing to a decision late in 2026. The REDEFINE 1 trial showed 20.4% weight loss at 68 weeks versus 14.9% for semaglutide alone [9]. Our CagriSema REDEFINE-1 results explainer covers the trial design and what the data means for the next-generation GLP-1 landscape.

Survodutide

Boehringer Ingelheim's dual glucagon/GLP-1 agonist targeting MASH (metabolic dysfunction-associated steatohepatitis) with liver fibrosis. It received FDA breakthrough therapy designation in September 2024. The phase 2 trial showed MASH improvement without worsening of fibrosis in 62% of patients on the highest dose, versus 14% on placebo [10].

The compounding reclassification

In April 2026 the FDA removed 12 peptides from its category 2 compounding list after their nominations were withdrawn. This is the most misread event in peptide regulation: removal from category 2 is not FDA approval, and it is not the same as being added to the 503A authorized bulk substances list.

In late 2023 the FDA placed a group of widely used peptides into category 2, its list of bulk drug substances that may present significant safety risks, which effectively stopped compounding pharmacies from preparing them. The list included BPC-157, TB-500, GHK-Cu, KPV, MOTS-c, Semax, Epitalon, and others.

On 15 April 2026 the FDA removed 12 peptides from category 2 after the nominations supporting their listing were withdrawn: BPC-157, LL-37, DiHexa, DSIP (emideltide), Epitalon, GHK-Cu (injectable only), KPV, PEG-MGF, Melanotan II, MOTS-c, Semax, and TB-500.

What that removal means: the explicit "significant safety risks" designation no longer applies to those 12 substances, and they become eligible to be considered for the 503A authorized bulk drug substances list.

What it does not mean: it is not FDA approval, and on its own it does not authorize compounding. Removal from category 2 does not place a substance on the 503A authorized list, which requires a separate advisory review and an FDA decision. A Pharmacy Compounding Advisory Committee meeting on 23 and 24 July 2026 is reviewing seven of the twelve (BPC-157, KPV, TB-500, MOTS-c, DSIP/emideltide, Semax, and Epitalon) for that authorized list, and the FDA's own briefing materials propose not adding them.

None of these peptides have completed phase 3 clinical trials for their commonly promoted uses, and none are FDA-approved for any condition. The clinical evidence for most of them remains limited to cell studies, animal models, and small uncontrolled human studies. For a detailed account of the reclassification and its practical implications, see the FDA category-2 reclassification explainer. For background on the chemistry differences between approved drugs and research peptides, the natural vs synthetic peptides guide covers the four origin categories in plain English.

Six misconceptions that trip people up

Six claims come up constantly and all six are wrong: that "research use only" implies human safety, that personal use is legally protected, that off-label prescribing covers unapproved peptides, that leaving category 2 equals approval, that all peptides share a risk profile, and that compounded equals equivalent.

1. "Research use only" means it is safe for humans. False. RUO is a legal disclaimer for laboratory reagents, not a quality standard for human use. It explicitly means the product has not been validated for diagnostic or therapeutic application.
2. Personal use of unapproved peptides is legal. False. Buying peptides online outside a regulated pharmacy dispensing pathway has no legal protection. The FDA considers unapproved peptides sold for human use to be misbranded and adulterated drugs.
3. Off-label prescribing covers research peptides. False. Off-label use applies only to drugs already FDA-approved for at least one condition. BPC-157 has zero approvals, so off-label does not apply. A physician cannot legally prescribe an unapproved substance off-label.
4. Removal from category 2 equals FDA approval. False, and this is the single most common error since April 2026. Removal lifts a prohibition-style designation. It says nothing about efficacy, it does not place a substance on the 503A authorized list, and it is a regulatory pathway decision rather than a clinical endorsement.
5. All peptides carry the same risk profile. False. Semaglutide has completed trials in tens of thousands of patients. BPC-157's human safety data comes from a handful of small studies. Equating their risk profiles is a category error.
6. Compounded peptides are identical to FDA-approved versions. False. Compounded preparations have no guarantee of identity, purity, potency, or safety compared to manufactured pharmaceuticals. Quality depends entirely on the compounding pharmacy's standards and oversight.

If you are still working out whether any of this applies to you, the beginner's decision guide walks through the questions worth answering before the regulatory status of a specific compound matters at all. The explorer below lets you filter every peptide in our catalog by approval status, route, and category.